Snapshot from Jul 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Moderna secures EU RSV vaccine contract
Business vaccine supply deal

Moderna secures EU RSV vaccine contract

Analysis based on 6 articles · First reported Jul 09, 2026 · Last updated Jul 09, 2026

Sentiment
20
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The contract strengthens Moderna's position in the RSV vaccine market, potentially boosting revenue and market share. It also signals EU confidence in mRNA technology, which may positively impact Moderna's stock and the broader mRNA vaccine sector.

Pharmaceuticals Biotechnology
Event Summary

Moderna has secured a joint procurement framework contract with the International — European Commission to supply its respiratory syncytial virus (RSV) vaccine, mRESVIA, to six European countries: Austria, Denmark, Republic of Ireland, Luxembourg, Norway, and Portugal. The contract allows access to up to 24 million doses over four years, with no minimum order required, ahead of the 2026-2027 winter season. mRESVIA is an mRNA-based vaccine approved in the EU for adults aged 60 and older, with a recent EMA recommendation to expand to all adults 18+. The deal contrasts with a more hesitant US approach to mRNA vaccines. Moderna's competitors GSK and Pfizer have top-selling RSV vaccines globally.

Key Actions
90 Moderna secured contract International — European Commission
80 International — European Commission signed procurement Moderna
50 European Union — European Medicines Agency recommended license expansion Moderna
20 Hadja Lahbib announced procurement
Entities Involved
stock
Moderna
Moderna secured a major supply contract with the International — European Commission for its RSV vaccine, enhancing its commercial prospects and competitive position against GSK and Pfizer.
Importance 100.0 Sentiment 30.0
govactor
International — European Commission
The International — European Commission facilitated the joint procurement, supporting member states' preparedness for RSV season and promoting mRNA vaccine use.
Importance 80.0 Sentiment 10.0
govactor
European Union — European Medicines Agency
The EMA recommended expanding mRESVIA's license to all adults 18+, which may increase vaccine uptake.
Importance 40.0 Sentiment 5.0
cnt
Austria
Austria is one of six countries gaining access to Moderna's RSV vaccine, potentially reducing RSV burden on its healthcare system.
Importance 30.0 Sentiment 10.0
cnt
Denmark
Denmark is one of six countries gaining access to Moderna's RSV vaccine, potentially reducing RSV burden on its healthcare system.
Importance 30.0 Sentiment 10.0
cnt
Republic of Ireland
Republic of Ireland is one of six countries gaining access to Moderna's RSV vaccine, potentially reducing RSV burden on its healthcare system.
Importance 30.0 Sentiment 10.0
cnt
Luxembourg
Luxembourg is one of six countries gaining access to Moderna's RSV vaccine, potentially reducing RSV burden on its healthcare system.
Importance 30.0 Sentiment 10.0
cnt
Norway
Norway is one of six countries gaining access to Moderna's RSV vaccine, potentially reducing RSV burden on its healthcare system.
Importance 30.0 Sentiment 10.0
loc
Portugal
Portugal is one of six countries gaining access to Moderna's RSV vaccine, potentially reducing RSV burden on its healthcare system.
Importance 30.0 Sentiment 10.0
govactor
European Union — European Centre for Disease Prevention and Control
ECDC emphasized the importance of immunization in vulnerable groups, supporting the procurement.
Importance 20.0 Sentiment 0.0
stock
GSK plc
GSK's RSV vaccine Arexvy faces increased competition from Moderna's mRESVIA in the EU market.
Importance 20.0 Sentiment -10.0
stock
Pfizer
Pfizer's RSV vaccine Abrysvo faces increased competition from Moderna's mRESVIA in the EU market.
Importance 20.0 Sentiment -10.0
per
Hadja Lahbib
International — European Commissioner Hadja Lahbib announced the procurement, highlighting preparedness for winter season.
Importance 20.0 Sentiment 5.0
Relationships
Moderna related ↔ European Union — European Centre for Disease Prevention and Control
International — European Commission related ↔ European Union — European Medicines Agency
International — European Commission related ↔ Austria
International — European Commission related ↔ Denmark
International — European Commission related ↔ Republic of Ireland
International — European Commission related ↔ Norway
Austria related ↔ Denmark
Austria related ↔ Republic of Ireland
Austria related ↔ Norway
Denmark related ↔ Republic of Ireland
Denmark related ↔ Norway
Denmark related ↔ European Union — European Centre for Disease Prevention and Control
Republic of Ireland related ↔ Luxembourg
Republic of Ireland related ↔ Norway
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.